AV 1980R
Alternative Names: AV-1980RLatest Information Update: 22 Dec 2023
At a glance
- Originator Flinders University; Institute for Molecular Medicine; University of California at Irvine
- Developer Capo Therapeutics
- Class Alzheimer vaccines; Protein vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 22 Dec 2023 AV 1980R is still in preclinical trials in Alzheimer's disease in USA (IM) (Nuravax pipeline, December 2023)
- 22 Dec 2023 Nuravax plans to file an IND application with the US FDA for Alzheimer's disease (Prevention) in 2023
- 22 Dec 2023 Nuravax plans to file an IND application with the US FDA for Alzheimer's disease (Prevention) in 2023 (Nuravax pipeline, December 2023)